OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
July 28, 2023 07:01 ET
|
OKYO Pharma LTD
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCPSecond clinical...
PetVivo Holdings, Inc. Achieves National Distribution of Spryng to More than 450 Veterinary Clinics
July 20, 2023 08:20 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, July 20, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
July 13, 2023 08:00 ET
|
Incannex Healthcare
Highlights: Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain...
PETVIVO HOLDINGS, INC. ANNOUNCES RESCHEDULED EARNINGS CALL FOR THE YEAR ENDED MARCH 31, 2023
June 29, 2023 18:59 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, June 29, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...
PetVivo Reports Fiscal 2023 Full Year Financial Results
June 29, 2023 15:45 ET
|
PetVivo Holdings, Inc.
Conference call begins at 4:00 p.m. Central time today EDINA, MN, June 29, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the...
Dr. Jeremy Caplin Joins PetVivo Holdings, Inc. as the Director of Research
June 27, 2023 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, June 27, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2023 ENDED MARCH 31, 2023
June 26, 2023 14:25 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, June 26, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical...
PetVivo Holdings, Inc. Begins Process to Pursue Approval of Biomatrix Particulate Technology for Initial Human Indication
June 21, 2023 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo" or the “Company) an emerging biomedical device company focused on the commercialization of...
Dr. Thomas Yarbrough Joins PetVivo Holdings, Inc. as the Senior Research Director
June 05, 2023 10:55 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, June 05, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...
Dr. Maureen Dower Joins PetVivo Holdings, Inc. as a Senior Technical Services Veterinarian
June 01, 2023 08:00 ET
|
PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, June 01, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of...